FDA to hold meeting on CAD fetal monitors

TriMed Staff | | Health Imaging | Artificial Intelligence
The FDA is seeking feedback on evaluating and improving the effectiveness of fetal monitors that use computer-aided detection (CAD) technology.

To evaluate the technology, the agency is holding a free all-day workshop on the subject on Nov. 10 at its Silver Spring, Md., campus.

Attendees will discuss how to identify and differentiate the various categories of the devices and the corresponding levels of evidence needed to validate them. Participants also will discuss how current databases might be used to verify and validate algorithms for the devices.

TriMed Staff

Related Content

AI beats standard regression models at predicting lung cancer risk
AI reduces CT lung cancer screening workload by nearly 80%
How AI and CCTA help heart teams plan ahead before PCI
5 steps for evaluating radiology AI applications
Adaptable AI system detects subtle changes in imaging, has potential across multiple clinical settings
New algorithm models radiologists' eye movements to interpret chest X-rays

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.